NCT01338636View on ClinicalTrials.gov

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

February 29, 2016

Study Completion Date

May 31, 2016

Conditions

Exercise-induced Pulmonary Arterial Hypertension

Interventions

DRUG

Ambrisentan

5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston